Curasight A/S Sustainability Reports

Curasight A/S is a clinical-stage biotechnology company that develops targeted radionuclide therapies and companion diagnostics for cancer. The company utilizes its proprietary uPAR theranostic platform (uTRACE and uTREAT) to improve cancer diagnosis, risk stratification, and gentle treatment options.

Sector: Professional & technical services

Country: Denmark

Exchange: Nordic Growth Market

LEI: 984500C9E3ADR98F1070

FIGI: BBG006W2WT16

7 reports from 2018 to 2025

• Curasight A/S 2025 Annual Report
• Curasight A/S 2024 Annual Report
• Curasight A/S 2023 Annual Report
• Curasight A/S 2022 Annual Report
• Curasight A/S 2021 Annual Report